NASDAQ:CGTX Cognition Therapeutics (CGTX) Stock Price, News & Analysis $0.57 -0.04 (-6.56%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.56▼$0.6350-Day Range$0.55▼$2.3752-Week Range$0.54▼$2.95Volume347,068 shsAverage Volume480,547 shsMarket Capitalization$22.83 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Cognition Therapeutics alerts: Email Address Cognition Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside1,304.0% Upside$8.00 Price TargetShort InterestHealthy1.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.87) to ($0.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.49 out of 5 starsMedical Sector432nd out of 910 stocksBiological Products, Except Diagnostic Industry63rd out of 155 stocks 3.3 Analyst's Opinion Consensus RatingCognition Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCognition Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Cognition Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.92% of the float of Cognition Therapeutics has been sold short.Short Interest Ratio / Days to CoverCognition Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cognition Therapeutics has recently decreased by 63.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCognition Therapeutics does not currently pay a dividend.Dividend GrowthCognition Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGTX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Cognition Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for CGTX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows7 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.75% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cognition Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cognition Therapeutics are expected to decrease in the coming year, from ($0.87) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cognition Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cognition Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCognition Therapeutics has a P/B Ratio of 1.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cognition Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Cognition Therapeutics Stock (NASDAQ:CGTX)Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Read More CGTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGTX Stock News HeadlinesSeptember 3, 2024 | globenewswire.comCognition Therapeutics to Participate in Upcoming September 2024 Investor ConferencesAugust 28, 2024 | americanbankingnews.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $8.00 Average Price Target from AnalystsSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 28, 2024 | americanbankingnews.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $8.00 Consensus Target Price from AnalystsAugust 28, 2024 | americanbankingnews.comEquities Analysts Set Expectations for Cognition Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:CGTX)August 22, 2024 | markets.businessinsider.comCognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s DiseaseAugust 22, 2024 | globenewswire.comCognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's DiseaseAugust 12, 2024 | msn.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Q1 2024 Earnings Call TranscriptSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 11, 2024 | seekingalpha.comCognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call TranscriptAugust 8, 2024 | globenewswire.comCognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical UpdateAugust 7, 2024 | msn.comB. Riley Securities Downgrades Cognition Therapeutics (CGTX)August 5, 2024 | globenewswire.comCognition Therapeutics to Report Second Quarter 2024 Financial ResultsJuly 31, 2024 | msn.comCantor Fitzgerald Downgrades Cognition Therapeutics (CGTX)July 30, 2024 | marketwatch.comCognition Therapeutics Down 39% on Alzheimer's Drug Study NewsJuly 30, 2024 | bizjournals.comPittsburgh-founded company's clinical trial demonstrates 'consistent improvement' in Alzheimer's patientsJuly 30, 2024 | markets.businessinsider.comCognition Therapeutics Reports Improvement In Cognitive Outcomes In Phase 2 SHINE Study In AD.July 30, 2024 | msn.comCognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer’s diseaseSee More Headlines Receive CGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGTX CUSIPN/A CIK1455365 Webwww.cogrx.com Phone412-481-2210FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$14.00 Low Stock Price Target$1.00 Potential Upside/Downside+1,304.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-118.11% Return on Assets-84.49% Debt Debt-to-Equity RatioN/A Current Ratio3.07 Quick Ratio3.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book1.00Miscellaneous Outstanding Shares40,058,000Free Float31,746,000Market Cap$22.83 million OptionableNot Optionable Beta1.41 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Lisa Ricciardi (Age 64)CEO, President & Director Comp: $854.15kMr. John Brendan Doyle (Age 47)Chief Financial Officer Comp: $414.88kDr. Anthony O. Caggiano M.D. (Age 54)Ph.D., Chief Medical Officer and Head of R&D Comp: $616.27kDr. Steven A. Weissman Ph.D.VP & Head of CMCKey CompetitorsBolt BiotherapeuticsNASDAQ:BOLTMiNK TherapeuticsNASDAQ:INKTDaré BioscienceNASDAQ:DAREBrainstorm Cell TherapeuticsNASDAQ:BCLIElevation OncologyNASDAQ:ELEVView All CompetitorsInsiders & InstitutionsMercer Global Advisors Inc. ADVBought 24,050 shares on 8/12/2024Ownership: 0.240%Renaissance Technologies LLCSold 65,982 shares on 8/9/2024Ownership: 0.224%AIGH Capital Management LLCSold 1,596,507 shares on 8/7/2024Ownership: 0.751%CM Management LLCBought 25,000 shares on 8/2/2024Ownership: 0.499%Bangor Savings BankBought 10,000 shares on 7/16/2024Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions CGTX Stock Analysis - Frequently Asked Questions How have CGTX shares performed this year? Cognition Therapeutics' stock was trading at $1.85 at the beginning of the year. Since then, CGTX shares have decreased by 69.2% and is now trading at $0.5698. View the best growth stocks for 2024 here. How were Cognition Therapeutics' earnings last quarter? Cognition Therapeutics, Inc. (NASDAQ:CGTX) released its quarterly earnings data on Thursday, August, 8th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.04. When did Cognition Therapeutics IPO? Cognition Therapeutics (CGTX) raised $45 million in an initial public offering on Friday, October 8th 2021. The company issued 3,768,116 shares at a price of $11.00-$13.00 per share. Who are Cognition Therapeutics' major shareholders? Top institutional shareholders of Cognition Therapeutics include AIGH Capital Management LLC (0.75%), CM Management LLC (0.50%), Mercer Global Advisors Inc. ADV (0.24%) and Renaissance Technologies LLC (0.22%). Insiders that own company stock include Lisa Ricciardi, Peggy Wallace and Ellen B Richstone. View institutional ownership trends. How do I buy shares of Cognition Therapeutics? Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
